SCHEMBL162887

SCHEMBL162887

CCOC(=O)c1cc2ccccc2c(Cl)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.53
KMT2A Q03164 2/20 0.49
KDM4E B2RXH2 2/20 0.49
MAPK1 P28482 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
CDC25B P30305 2/20 0.48
APAF1 O14727 1/20 0.48
CASP3 P42574 1/20 0.48
CASP6 P55212 1/20 0.48
SENP8 Q96LD8 1/20 0.48
SENP7 Q9BQF6 1/20 0.48
SENP6 Q9GZR1 1/20 0.48
GABRA2 P47869 5/20 0.48
GABRB2 P47870 5/20 0.48
GABRP O00591 4/20 0.48
GABRD O14764 4/20 0.48
GABRA1 P14867 4/20 0.48
GABRB1 P18505 4/20 0.48
GABRG2 P18507 4/20 0.48
GABRB3 P28472 4/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11371994 0.84 KDM4E (0.57) CYP1A2KMT2AKDM4EMAPK1L3MBTL1
SCHEMBL2624126 0.84 CYP1A2 (0.54) CYP1A2KMT2AKDM4EMAPK1L3MBTL1
SCHEMBL3281702 0.83 KDM4E (0.50) CYP1A2KMT2AKDM4EMAPK1L3MBTL1
SCHEMBL23956778 0.82 KDM5A (0.46) CYP1A2KMT2AKDM4EMAPK1GABRA2
SCHEMBL22392847 0.82 ALDH1A1 (0.61) CYP1A2MAPK1GABRA2GABRB2GABRA1
SCHEMBL31373449 0.82 CYP1A2 (0.45) CYP1A2KMT2AKDM4EMAPK1GABRA2
SCHEMBL212240 0.82 CYP1A2 (0.45) CYP1A2KMT2AKDM4EMAPK1GABRA2
SCHEMBL10984807 0.81 TSPO (0.60) CYP1A2KMT2AKDM4EMAPK1L3MBTL1
Hydrochloric Acid SCHEMBL6980556 0.81 ALDH1A1 (0.52) CYP1A2KMT2AKDM4EMAPK1L3MBTL1
SCHEMBL13064917 0.80 CYP1A2 (0.54) CYP1A2KMT2AKDM4EMAPK1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2663553-B1 QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR USE AS JAK MODULATORS AMBIT BIOSCIENCES CORP (US) 2015-08-26 EP disclosed
EP-2663553-A2 QUINOLINE AND ISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF Ambit Biosciences Corporation (US) 2013-11-20 EP disclosed
US-20130296363-A1 QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR USE AS JAK MODULATORS AMBIT BIOSCIENCES CORPORATION (US) 2013-11-07 US disclosed
WO-2012030944-A2 QUINOLINE AND ISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130296363-A1 QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR USE AS JAK MODULATORS JAK3, JAK2, JAK1 CYP1A2 1736/4885KMT2A 733/4885KDM4E 1365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.